Nat Commun:病理图像的生物信息学分析能够促使TFE3 Xp11.2易位性肾细胞癌更好的诊断

2020-05-04 AlexYang MedSci原创

与其他RCC亚型相比,TFE3 Xp11.2易位性肾细胞癌(TFE3-RCC)一般会发展成为更加具有侵袭性的癌症。另外,该类型的癌症很难通过病理图像的视觉检查来进行诊断。

与其他RCC亚型相比,TFE3 Xp11.2易位性肾细胞癌(TFE3-RCC)一般会发展成为更加具有侵袭性的癌症。另外,该类型的癌症很难通过病理图像的视觉检查来进行诊断。

最近,有研究人员收集了74个TFE3-RCC案例的苏木精和伊红染色组织病理学整个图像(目前为止是最大的群体)和74个透明细胞RCC案例的苏木精和伊红染色组织病理学整个图像(ccRCC,最常见的RCC亚型),并且两组之间的性别和肿瘤等级是匹配的。之后,研究人员进行了自动化的生信分析通道来提取成像特征。比较研究鉴定了TFE3-RCC和ccRCC图像特征之间存在52个不同的特征。研究人员建立了机器学习模型来区分ccRCC和TFE3-RCC。外部验证集合对分类模型的测试表明了其具有高度的准确性,ROC面积为0.842到0.894。

最后,研究人员指出,他们的结果表明了自动化的图像特征识别能够捕捉TFE3-RCC和ccRCC之间细小的形态差异,为TFE3-RCC的诊断提供了指导。

原始出处:

Jun Cheng, Zhi Han, Rohit Mehra et al. Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma. Nat Commun. 14 April 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798451, encodeId=9f291e98451d6, content=<a href='/topic/show?id=ad896919381' target=_blank style='color:#2F92EE;'>#生物信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69193, encryptionId=ad896919381, topicName=生物信)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Apr 08 23:39:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978970, encodeId=100f19e8970fa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Jul 20 17:39:44 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087686, encodeId=1d02208e6864a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 27 06:39:44 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798468, encodeId=77cf1e98468e9, content=<a href='/topic/show?id=7915691984e' target=_blank style='color:#2F92EE;'>#生物信息学分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69198, encryptionId=7915691984e, topicName=生物信息学分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Jun 21 21:39:44 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038366, encodeId=a0f3203836670, content=<a href='/topic/show?id=22b018849fd' target=_blank style='color:#2F92EE;'>#Xp11.2易位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18849, encryptionId=22b018849fd, topicName=Xp11.2易位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jan 24 05:39:44 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884299, encodeId=09ba188429918, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 30 01:39:44 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382504, encodeId=19e0382504a8, content=这个想法好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue May 05 06:40:12 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798451, encodeId=9f291e98451d6, content=<a href='/topic/show?id=ad896919381' target=_blank style='color:#2F92EE;'>#生物信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69193, encryptionId=ad896919381, topicName=生物信)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Apr 08 23:39:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978970, encodeId=100f19e8970fa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Jul 20 17:39:44 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087686, encodeId=1d02208e6864a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 27 06:39:44 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798468, encodeId=77cf1e98468e9, content=<a href='/topic/show?id=7915691984e' target=_blank style='color:#2F92EE;'>#生物信息学分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69198, encryptionId=7915691984e, topicName=生物信息学分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Jun 21 21:39:44 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038366, encodeId=a0f3203836670, content=<a href='/topic/show?id=22b018849fd' target=_blank style='color:#2F92EE;'>#Xp11.2易位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18849, encryptionId=22b018849fd, topicName=Xp11.2易位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jan 24 05:39:44 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884299, encodeId=09ba188429918, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 30 01:39:44 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382504, encodeId=19e0382504a8, content=这个想法好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue May 05 06:40:12 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1798451, encodeId=9f291e98451d6, content=<a href='/topic/show?id=ad896919381' target=_blank style='color:#2F92EE;'>#生物信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69193, encryptionId=ad896919381, topicName=生物信)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Apr 08 23:39:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978970, encodeId=100f19e8970fa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Jul 20 17:39:44 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087686, encodeId=1d02208e6864a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 27 06:39:44 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798468, encodeId=77cf1e98468e9, content=<a href='/topic/show?id=7915691984e' target=_blank style='color:#2F92EE;'>#生物信息学分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69198, encryptionId=7915691984e, topicName=生物信息学分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Jun 21 21:39:44 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038366, encodeId=a0f3203836670, content=<a href='/topic/show?id=22b018849fd' target=_blank style='color:#2F92EE;'>#Xp11.2易位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18849, encryptionId=22b018849fd, topicName=Xp11.2易位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jan 24 05:39:44 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884299, encodeId=09ba188429918, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 30 01:39:44 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382504, encodeId=19e0382504a8, content=这个想法好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue May 05 06:40:12 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
    2020-11-27 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1798451, encodeId=9f291e98451d6, content=<a href='/topic/show?id=ad896919381' target=_blank style='color:#2F92EE;'>#生物信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69193, encryptionId=ad896919381, topicName=生物信)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Apr 08 23:39:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978970, encodeId=100f19e8970fa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Jul 20 17:39:44 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087686, encodeId=1d02208e6864a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 27 06:39:44 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798468, encodeId=77cf1e98468e9, content=<a href='/topic/show?id=7915691984e' target=_blank style='color:#2F92EE;'>#生物信息学分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69198, encryptionId=7915691984e, topicName=生物信息学分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Jun 21 21:39:44 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038366, encodeId=a0f3203836670, content=<a href='/topic/show?id=22b018849fd' target=_blank style='color:#2F92EE;'>#Xp11.2易位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18849, encryptionId=22b018849fd, topicName=Xp11.2易位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jan 24 05:39:44 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884299, encodeId=09ba188429918, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 30 01:39:44 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382504, encodeId=19e0382504a8, content=这个想法好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue May 05 06:40:12 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1798451, encodeId=9f291e98451d6, content=<a href='/topic/show?id=ad896919381' target=_blank style='color:#2F92EE;'>#生物信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69193, encryptionId=ad896919381, topicName=生物信)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Apr 08 23:39:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978970, encodeId=100f19e8970fa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Jul 20 17:39:44 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087686, encodeId=1d02208e6864a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 27 06:39:44 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798468, encodeId=77cf1e98468e9, content=<a href='/topic/show?id=7915691984e' target=_blank style='color:#2F92EE;'>#生物信息学分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69198, encryptionId=7915691984e, topicName=生物信息学分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Jun 21 21:39:44 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038366, encodeId=a0f3203836670, content=<a href='/topic/show?id=22b018849fd' target=_blank style='color:#2F92EE;'>#Xp11.2易位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18849, encryptionId=22b018849fd, topicName=Xp11.2易位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jan 24 05:39:44 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884299, encodeId=09ba188429918, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 30 01:39:44 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382504, encodeId=19e0382504a8, content=这个想法好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue May 05 06:40:12 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1798451, encodeId=9f291e98451d6, content=<a href='/topic/show?id=ad896919381' target=_blank style='color:#2F92EE;'>#生物信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69193, encryptionId=ad896919381, topicName=生物信)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Apr 08 23:39:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978970, encodeId=100f19e8970fa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Jul 20 17:39:44 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087686, encodeId=1d02208e6864a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 27 06:39:44 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798468, encodeId=77cf1e98468e9, content=<a href='/topic/show?id=7915691984e' target=_blank style='color:#2F92EE;'>#生物信息学分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69198, encryptionId=7915691984e, topicName=生物信息学分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Jun 21 21:39:44 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038366, encodeId=a0f3203836670, content=<a href='/topic/show?id=22b018849fd' target=_blank style='color:#2F92EE;'>#Xp11.2易位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18849, encryptionId=22b018849fd, topicName=Xp11.2易位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jan 24 05:39:44 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884299, encodeId=09ba188429918, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 30 01:39:44 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382504, encodeId=19e0382504a8, content=这个想法好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue May 05 06:40:12 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
    2020-08-30 liye789132251
  7. [GetPortalCommentsPageByObjectIdResponse(id=1798451, encodeId=9f291e98451d6, content=<a href='/topic/show?id=ad896919381' target=_blank style='color:#2F92EE;'>#生物信#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69193, encryptionId=ad896919381, topicName=生物信)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Apr 08 23:39:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978970, encodeId=100f19e8970fa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Jul 20 17:39:44 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087686, encodeId=1d02208e6864a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Nov 27 06:39:44 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798468, encodeId=77cf1e98468e9, content=<a href='/topic/show?id=7915691984e' target=_blank style='color:#2F92EE;'>#生物信息学分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69198, encryptionId=7915691984e, topicName=生物信息学分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Jun 21 21:39:44 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038366, encodeId=a0f3203836670, content=<a href='/topic/show?id=22b018849fd' target=_blank style='color:#2F92EE;'>#Xp11.2易位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18849, encryptionId=22b018849fd, topicName=Xp11.2易位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sun Jan 24 05:39:44 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884299, encodeId=09ba188429918, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 30 01:39:44 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382504, encodeId=19e0382504a8, content=这个想法好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue May 05 06:40:12 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
    2020-05-05 njwbhuang

    这个想法好。

    0

相关资讯

日本批准CABOMETYX(cabozantinib)治疗无法切除的或转移性肾细胞癌

Exelixis制药公司今日宣布,CABOMETYX®(cabozantinib)已获得日本厚生劳动省的批准,用以治疗无法切除的或转移性肾细胞癌(RCC)患者。

Modern Pathology:反极性乳头状肾细胞癌中鉴定了复发性KRAS突变

综合性的分子分析阐释了乳头状肾细胞肿瘤(PRCC)是一种异质性的实体瘤。反极性乳头状肾肿瘤(PRNRP)是PRCC的子集,具有自身的特征组织形态,比如低等级的核特征,倒置的核位置,嗜酸性的细胞质,以及懒惰的临床行为。最近,有研究人员通过比较1型PRCC(PRCC1)和2型PRCC(PRCC2)尝试确定了PRNRP的分子、临床病理、组织学混合免疫组化特征。研究共包括了30个PRNRP案例,23个PR

Nat Commun:中国透明细胞肾细胞癌的整体基因组研究阐释了与血栓相关的特性

透明细胞肾细胞癌(ccRCC)是一种异质性的疾病,不同的种族具有不同的特性。而关于中国人ccRCC的基因组的系统性鉴定仍旧缺乏,并且与癌栓(TT)相关的ccRCC特性(ccRCC-TT)仍旧不清楚。最近,有研究人员应用全外显子组测序的的方法对110个正常-肿瘤配对和42个正常-肿瘤-血栓配对进行了分析,并对61个肿瘤-正常配对和30个原发性肿瘤-血栓配对进行了转录组测序分析,这些患者来源于152名

Sci Rep:鉴定治疗响应的基因特性来指导透明细胞肾细胞肿瘤的精准的肿瘤学研究

透明细胞肾细胞癌(ccRCC)是一种常见抗性疾病,并且具有异常的血管生成和免疫抑制特征。患有转移性疾病的患者可根据临床特征进行治疗:低风险患者通常使用抗血管生成药物,中/高风险患者通常使用免疫治疗。然而,目前还没有可使用的生物标记来指导这些患者进行治疗的选择。最近,一个发表的临床II期试验观察到了ccRCC患者的聚类与靶向治疗响应存在联系。然而,这些组别的聚类并不清晰。因此,有研究人员对469名c

AACR 2020:基因治疗肾细胞癌获突破,DCR可达75%!

溶瘤病毒用于肿瘤治疗被寄予厚望,作为下一代的基因疗法的主要手段。虽然它还有很多缺点,如瘤内给药的操作不够便捷、易产生中和抗体无法实现系统给药、单药使用应答率不高。而且第一个溶瘤病毒T-vec的获批上市

Cell Death Dis:BRD4,治疗肾细胞癌的新潜在靶基因

肾癌是一种重要的公共卫生问题,目前全世界每年约有33.8万的新发肾癌以及144000例的死亡病例。肾细胞癌(RCC)约占此类恶性肿瘤的85%。在美国,其是男性第六大最常见的癌症,在女性中是第八大。